Vivimed Labs confirms no encumbrance on promoter shares in FY26
Vivimed Labs filed disclosures with BSE and NSE confirming that its promoters did not create any encumbrance on their shareholdings during the financial year ended March 31, 2026. The declaration was submitted in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary Kopparthi Yugandhar submitted the filing on behalf of the company.
*this image is generated using AI for illustrative purposes only.
Vivimed Labs has confirmed to the stock exchanges that its promoters did not encumber any shares held in the company during the financial year ended March 31, 2026. This disclosure ensures that the shareholding structure remains free of liens or charges, providing stability to the company's equity base.
The company submitted the declaration to BSE Limited and the National Stock Exchange of India Limited on April 6, 2026. The filing was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates annual disclosures regarding encumbrances on promoter holdings.
Santosh Varalwar, a promoter of the company, provided the confirmation on behalf of all promoters. The letter explicitly stated that no encumbrance was made directly or indirectly on the shares held by them in Vivimed Labs Limited during the specified period.
The filing was signed and submitted by Kopparthi Yugandhar, Company Secretary of Vivimed Labs Limited. The document included the necessary corporate identification details and was addressed to the respective stock exchanges for their records and information.
| Detail | Information |
|---|---|
| Regulation | SEBI (SAST) Regulations, 2011, Reg 31(4) |
| Financial Year | Year ended March 31, 2026 |
| Encumbrance Status | No encumbrance made by promoters |
| Filing Date | April 6, 2026 |
| Promoter Signatory | Santosh Varalwar |
| Company Secretary | Kopparthi Yugandhar |
Historical Stock Returns for Vivimed Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.32% | -3.86% | -9.26% | -77.52% | -77.52% | -4.32% |
How will this confirmation impact investor confidence and the stock's liquidity in the upcoming quarter?
Does the absence of share encumbrance indicate potential for future capital raising or strategic acquisitions by the promoters?
What are the expected financial performance targets for Vivimed Labs in the fiscal year following this disclosure?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
